At the Experimental Therapeutics Institute, our goal is to exploit opportunities from new biological insights to produce novel therapeutics. Our unique, integrated academic drug discovery program at the Icahn School of Medicine at Mount Sinai (ISMMS) covers target discovery, validation in novel models, and lead generation of both small molecules and biologics. We are a multidisciplinary team, and our broad capabilities include state-of-the-art screening facilities, medicinal chemistry, pluripotent stem cells, rational design, and monoclonal antibody development.
We are a hub for the development of new drugs that result from basic and clinical research programs throughout the Mount Sinai Health System. We offer an integrated collaborative approach, utilizing high throughput screening systems to model and validate novel biological discoveries. Our work is crucial to all stem cell research at ISMMS and fundamental to translational grants.